Primary |
Product Used For Unknown Indication |
18.0% |
Acquired Haemophilia |
13.4% |
Factor Viii Inhibition |
13.2% |
Haemophilia |
8.8% |
Haemostasis |
8.6% |
Factor Viii Deficiency |
6.6% |
Prophylaxis |
4.6% |
Haemorrhage |
3.4% |
Pain |
3.2% |
Off Label Use |
2.8% |
Post Procedural Haemorrhage |
2.6% |
Tooth Abscess |
2.0% |
Drug Use For Unknown Indication |
1.8% |
Haemorrhage Prophylaxis |
1.8% |
Premedication |
1.8% |
Diabetes Mellitus |
1.6% |
Hypertension |
1.6% |
Insomnia |
1.6% |
Anaemia |
1.4% |
Haemarthrosis |
1.4% |
|
Hepatitis B Surface Antibody Positive |
12.8% |
Drug Ineffective |
10.4% |
Renal Failure |
9.6% |
Factor Viii Inhibition |
7.2% |
Blood Fibrinogen Decreased |
5.6% |
Haemorrhage |
5.6% |
Haemorrhagic Stroke |
5.6% |
Disseminated Intravascular Coagulation |
4.8% |
Hepatitis B Antibody Positive |
4.8% |
Haemarthrosis |
4.0% |
Pneumonia |
4.0% |
Anaphylactic Shock |
3.2% |
Death |
3.2% |
Fibrin D Dimer Increased |
3.2% |
Ischaemic Stroke |
3.2% |
Vomiting |
3.2% |
Cerebrovascular Accident |
2.4% |
Deep Vein Thrombosis |
2.4% |
Drug Effect Decreased |
2.4% |
Post Procedural Haemorrhage |
2.4% |
|
Secondary |
Factor Viii Inhibition |
46.4% |
Prophylaxis |
19.3% |
Product Used For Unknown Indication |
5.9% |
Acquired Haemophilia |
5.8% |
Factor Viii Deficiency |
4.5% |
Pain |
2.2% |
Haemophilia |
1.8% |
Haemostasis |
1.8% |
Premedication |
1.7% |
Haemorrhage |
1.3% |
Haematoma |
1.3% |
Tooth Abscess |
1.3% |
Depression |
1.1% |
Haemarthrosis |
1.1% |
Hypertension |
0.9% |
Anaemia |
0.9% |
Infection Prophylaxis |
0.7% |
Muscle Haemorrhage |
0.7% |
Agitation |
0.6% |
Constipation |
0.6% |
|
Hepatitis B Surface Antibody Positive |
76.5% |
Hepatitis B Surface Antigen Positive |
7.0% |
Haemarthrosis |
4.2% |
Blood Fibrinogen Decreased |
2.5% |
Hepatitis B Antibody Positive |
1.7% |
Oedema Peripheral |
1.3% |
Pneumonia |
1.0% |
Drug Effect Decreased |
0.8% |
Enterobacter Infection |
0.8% |
Drug Ineffective |
0.7% |
Thrombophlebitis Superficial |
0.7% |
Renal Failure |
0.4% |
Leukocytosis |
0.4% |
Factor Viii Inhibition |
0.4% |
Ileus Paralytic |
0.4% |
Haemorrhage |
0.3% |
Thrombosis |
0.3% |
Disseminated Intravascular Coagulation |
0.2% |
Vomiting |
0.2% |
Arthralgia |
0.2% |
|
Concomitant |
Hiv Infection |
22.9% |
Acquired Haemophilia |
10.2% |
Drug Use For Unknown Indication |
9.3% |
Haemophilia A With Anti Factor Viii |
8.5% |
Immunosuppressant Drug Therapy |
7.6% |
Haemostasis |
5.9% |
Factor Viii Deficiency |
4.2% |
Haemorrhage |
4.2% |
Retroperitoneal Haematoma |
3.4% |
Diarrhoea |
2.5% |
Haemarthrosis |
2.5% |
Haemophilia |
2.5% |
Hepatitis C |
2.5% |
Insomnia |
2.5% |
Muscle Haemorrhage |
2.5% |
Adverse Event |
1.7% |
Bipolar Disorder |
1.7% |
Cerebral Haemorrhage |
1.7% |
Coagulopathy |
1.7% |
Factor Viii Inhibition |
1.7% |
|
Multi-organ Failure |
11.9% |
Pyrexia |
11.9% |
Death |
7.1% |
Osteonecrosis |
7.1% |
Thrombosis |
7.1% |
Cerebral Haemorrhage |
4.8% |
Drug Ineffective |
4.8% |
Haematoma |
4.8% |
Muscle Haemorrhage |
4.8% |
Renal Haemorrhage |
4.8% |
Sudden Death |
4.8% |
Tachycardia |
4.8% |
Transmission Of An Infectious Agent Via A Medicinal Product |
4.8% |
Abdominal Pain |
2.4% |
Agranulocytosis |
2.4% |
Cerebellar Haemorrhage |
2.4% |
Cholelithiasis |
2.4% |
Face Injury |
2.4% |
Factor Viii Inhibition |
2.4% |
Hypersensitivity |
2.4% |
|